Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Friday, September 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gossamer Bio, Inc. has announced a 1-for-80 reverse stock split to enhance its stock structure. The company has filed a Certificate of Amendment with the Delaware Secretary of State. This move is aimed at improving market perception and potentially attracting more institutional investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Gossamer Bio is taking steps to enhance its stock structure.
  • The reverse stock split may improve the company's market perception.
  • This action could attract more institutional investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to eff

Frequently Asked Questions

What is the purpose of Gossamer's reverse stock split?

The reverse stock split aims to enhance the company's stock structure and market perception.

What is the ratio of Gossamer's reverse stock split?

Gossamer Bio announced a 1-for-80 reverse stock split.

Where was the amendment for the stock split filed?

The amendment was filed with the Secretary of State of Delaware.

What is Gossamer Bio's focus area?

Gossamer Bio focuses on developing treatments for pulmonary arterial hypertension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Gossamer Bio reverse stock split pulmonary arterial hypertension clinical-stage biopharmaceutical
Last updated: Sep 11, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →